Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

10.1002/jha2.548

Saved in:
Bibliographic Details
Main Authors: Spencer, Andrew, Samoilova, Olga, Chng, Wee-Joo, Labotka, Richard, Li, Cong, Wu, Kwang-Wei, Saxena, Nakul, Yan, Xu, Lee, Jae Hoon, Beksac, Meral
Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
Format: Article
Published: Wiley 2023
Subjects:
emerging‐markets
ixazomib
multiple myeloma
overall survival
proteasome inhibitor
Online Access:https://scholarbank.nus.edu.sg/handle/10635/237497
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

https://scholarbank.nus.edu.sg/handle/10635/237497

Similar Items